StockWatch
·

JAGSONPAL PHARMACEUTICALS LTD. Q2 FY27 Results

JAGSNPHARMQ2 FY27 Results
Filing
Result:Steady· Market: Crashed#Margin squeeze#One-off hit

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)
Revenue96.37
Total Income98.62
Expenditure81.97
PBT16.42
Net Profit12.29
OPM17.29%
NPM12.46%
EPS1.86
View full financials

Standalone revenue grew a healthy 9.3% YoY but adjusted PAT was roughly flat (+2%) as OPM compressed to ~20.6% from 22.1% on higher employee/ESOP and D&A costs, making this an in-line quarter for the sector despite the margin squeeze.

JAGSONPAL PHARMACEUTICALS LTD. · QQ2 FY-2027 · THE CALL

Mission 2028 on track, but Q2 organic growth lags targets

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

03 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Reaffirmed INR500Cr vision and margins; hit acquisition milestones (Aequitas, Group Pharma integrated). Missed organic growth target (9.3% vs 10%+, vs 1.5x IPM claimed). Early stage on integrations.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Clear multi-year vision (INR500Cr by FY28) backed by acquisitions + field force expansion to 10K doctors across 4 therapies. But Q2 organic growth of 9.3% undershot 10%+ guidance and 1.5x IPM target; PAT declined -2.3% YoY despite revenue growth, signaling margin compression from hospital channel integration. Execution risk is material.

₹96.4 Cr

Revenue · +29.4% YoY

₹12.3 Cr

Reported PAT · −2.3% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Organic growth accelerating, 10%+ CAGR, outperforming IPM

Q2 standalone +9.3% YoY, below IPM ~12%, below stated 10% target

OVERSTATED

Maintaining 1.5x IPM growth trajectory (from Q1 call)

9.3% organic growth vs ~12% IPM = 0.78x, not 1.5x

MISS

Strong organic momentum on back of power brands and new launches

9.3% organic, margins compressed YoY, PAT down -2.3% despite revenue growth

OVERSTATED

Clear road map to INR500 crores by FY28 without further large acquisitions

Already done 2 acquisitions in 6 months (Yash Pharma, Aequitas, Group Pharma); consolidated revenue +29% but organic only +9.3%

Partially Overstated

Hospital channel integration smooth, synergies visible

Aequitas only 1 quarter old, Group Pharma 1 month old; no Q2 financials for Group Pharma; early to claim success

Unverified

Earnings quality

What changed since the last call

Deltas vs. the prior call

INR500 crores mission reaffirmed

Neutral

Consistent with Q1 guidance (Jan 2026 call). No change in target, but added Group Pharma acquisition as third inorganic pillar.

Hospital channel now core strategy

Upgrade

Aequitas (July) + Group Pharma Wellness (Oct) acquired; now pursuing 11%+ hospital revenue mix. Prior strategy was pure Rx trade channel.

Organic growth guidance implicitly downgraded

Downgrade

Q1 implied 10%+ organic target; Q2 delivered 9.3%. Claimed still 'on track' but trajectory softening vs expectations.

Field force expansion accelerating

Upgrade

Plan to reach ~10K doctors (from ~1.37K) to cross-sell into Aequitas institutional channel. New organizational capability vs Q1.

The Q&A

Sajal Kapoor (Antfragilis) pushed hard on organic growth miss: challenged 10% and 1.5x IPM guidance vs actual 9.3% and ~0.78x IPM delivered. Management held firm but evasive—said 'things have started looking up' without addressing why targets were missed. On 5-year vision and manufacturing backend strategy, management deferred to board/promoters. Analysts pressed on margin trajectory and brand specifics; management confident but non-specific on which brands drive Q4 recovery.

The exchanges that mattered

INR500 crores vision credibility — Ankur Kumar, Alpha Capital

Answered

Clear roadmap with execution. Growth faster from Q3. Investments in product, people, capabilities are setting up Q3 onwards.

Blended business EBITDA margin — Ankur Kumar, Alpha Capital

Answered

Confident of 22% EBITDA margin at scale. Standalone will be much higher. Hospital lower (70%-80% gross margin business).

Q3 margin guidance — Ankur Kumar, Alpha Capital

Answered

Q3 will deliver more than 22%. Q4 is drag (seasonal India). On 3-quarter basis, very close to 22% or more.

Organic growth vs IPM — Sajal Kapoor, Antfragilis Thinking

Partial

Market growing at 12% to 16.8%. We've been flattish at around 10%. Our growth will accelerate. Branded Rx upward of 10%.

Organic vs inorganic split — Sajal Kapoor, Antfragilis Thinking

Answered

Yes, we will provide it from Q3 deck onwards in commentary.

5-year vision beyond 2028 — Sajal Kapoor, Antfragilis Thinking

Dodged

Mission 2028 is our focus. Beyond that, in discussion with promoters/board. Will come back with more granular detail.

Aequitas rationale — Mihir Damania, Fident Asset Management

Answered

Legacy Jagsonpal weak in hospital. Industry moved 11%+ to hospital channel. Aequitas provided niche entry, co-sell Jagsonpal brands into their channel.

Indocap/Equirex de-growth — Urmish Shah, Moneyvisers

Answered

Indocap: legacy brand, old molecule, innovation underway (results expected Nov). Equirex: NRx-restricted, category pricing dependent. Will double-down on both.

Group Pharma business margins — Harshil Parekh, BTH Capital

Answered

Similar to Jagsonpal.

PAT guidance for FY28 — Gulam Soni, Individual Investor

Partial

With the sales and EBITDA margin guidance we've given, you can decipher the numbers. Do the math.

Sustainable gross margin blended business — Vansh Gupta, Prescient Capital

Answered

Standalone is branded business, will improve 50-75 bps year-to-year. Aequitas much lower (hospital). Each follows own trajectory.

Which brands will drive Q4 growth? — Vansh Gupta, Prescient Capital

Partial

Top 10 brands are 60% of revenue, will contribute majority. New brands take quarters/years to scale.

Aequitas ramp-up challenges — Vansh Gupta, Prescient Capital

Answered

Not at all. Hospital business rate-driven, contract-based. Supply chain work ongoing, benefits from Q4.

Aequitas INR100 crores guidance — Vansh Gupta, Prescient Capital

Answered

For the full year, yes. Nothing changes for us.

Guidance

Forward guidance and management's confidence

INR500 crores by FY28 (Mission 2028)

Medium

Dependent on pure organic growth (~10% CAGR on INR300Cr base) + synergies from Aequitas/Group Pharma. No further large M&A planned. Q3 to cross INR100Cr.

INR100+ crores standalone by end FY27

Medium

Requires ~23% QoQ growth from INR81Cr Q2 to hit. Q3 typically strong; hospital channel ramp-up. Ambitious but stated confidently.

22% EBITDA margin at INR500Cr scale

Medium

Standalone currently 22.7% H1. Hospital channel (Aequitas, Group Pharma) lower margin will drag consolidated. Confident margins sustainable once Aequitas >50% at maturity.

Standalone gross margin ~65% sustainable (improving 50-75 bps YoY)

High

Currently 64.1%, targeting premium positioning. Hospital channel (Group Pharma 70-80% gross) will improve from supply chain synergies.

Risks the call surfaced

Ranked by how much they should concern a holder

Organic growth shortfall

High

Standalone +9.3% YoY vs 10%+ guidance and claimed 1.5x IPM growth. Market growing ~12-16%, company growing slower. Indicates market share loss in branded Rx segment.

Hospital channel margin risk

High

Aequitas (hospital/institutional) and Group Pharma (critical care) are lower-margin businesses (70%-80% gross vs 64% standalone). Will structurally depress consolidated EBITDA and PAT unless supply chain + pricing synergies realized.

Aequitas integration execution

Medium

Aequitas acquired July 2026 (1 quarter old); only 1 full quarter in Q2 results. Supply chain work ongoing; benefits said to accrue Q4. Early to confirm integration success; re-negotiation of contracts, pricing pressure possible.

Legacy brand de-growth persistence

Medium

Indocap (GP/ortho) and Equirex (NRx-restricted dermatology) declining despite claimed innovation pipeline. Indocap older molecule, Equirex NRx-driven and restricted market. May not revive on timeline.

Field force expansion execution risk

Medium

Plan to expand field force from 1.37K to 10K doctors (7.3x growth) is capex + talent heavy. New capability to support institutional channel cross-selling. Hiring, training, retention risk.

Management

Score 6/10. Confident and detailed on strategy and acquisitions. Evasive on 5-year vision and manufacturing backend questions. Deferred to board/promoters on strategic direction beyond FY28. Numbers-focused on EBITDA, vague on PAT guidance. Delivered acquisitions on plan (Aequitas July, Group Pharma Oct). Integration progressing (Aequitas 1 quarter, Group Pharma 1 month). Missed organic growth target (9.3% vs 10%+) and implicit 1.5x IPM guidance. PAT down -2.3% YoY despite revenue growth; execution not translating to bottom-line.

What to watch next
  • 1 · Q3 FY27

    Target INR100+ crores standalone revenue; test 23% QoQ growth claim

  • 2 · Q4 FY27

    Group Pharma wellness portfolio ramp-up; Aequitas supply chain synergies accrue

  • 3 · Nov 2026

    First value-added launch from Aequitas; test inorganic integration model

Execution risk is material.

Informational and educational content only. Not investment advice.